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Figure 1. Extracellular matrix degradation. Bovine FDC explants were
cultured with indicated treatments for 27 days. Supernatant were moni-
tored by biomarkers of cartilage degradation C2M, AGNx1 and AGNx2
(Nordic Bioscience A/S). Values are mean  SEM. One-way ANOVA was
used to compare each bar with its respective W/O. *P < 0.05, **P < 0.01.
Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489S76Conclusions: This study shows that in patients with hip OA the urinary
biochemical markers uCTX-II and uCIIM are not cross-sectionally
associated with hip pain during the 2-year follow-up. However, the
uCTX-II level at baseline could predict a progressive or moderate hip
pain trajectory over a two-year follow-up period.
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EXTRACELLULAR MATRIX CHANGES IN RESPONSE TO RECOMBINANT
HUMAN FIBROBLAST GROWTH FACTOR 18 STUDIED IN EX VIVO
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Purpose: Osteoarthritis (OA) is a degenerative disease with high
prevalence, creating an unmet medical need for drugs to regenerate
cartilage. A promising candidate for a novel disease modifying osteo-
arthritis drug (DMOAD) is Sprifermin, a truncated form of ﬁbroblast
growth factor 18 (FGF18). Sprifermin has been demonstrated to
increase cartilage volume in the knees of OA patients, but surprisingly
little is known about the mode of action behind its anabolic effects.
The few studies published indicate that full-length FGF18 induces
cartilage formation by increasing chondrocyte proliferation, resulting
in increased overall matrix production by the larger population of
chondrocytes. Our hypothesis is that matrix degradation is initially
needed during this process in order to expand the lacunae and make
room in the matrix for the new chondrocytes. Accordingly, the aim of
this study was to characterize the changes in matrix degradation
occurring in response to direct stimulation with recombinant human
(rh) FGF18.
Methods: Full depth cartilage explants (FDCex) punched from bovine
articular cartilage were cultured for 27 days. In replicates of six, the
FDCex were treated with various concentrations of full-length rhFGF18
(1, 10, 50, 100 or 500 ng/mL rhFGF18), an anabolic cytokine as positive
control for cartilage formation (100 ng/mL IGF-I), or culture media
without treatment as negative control (W/O). Supernatants were har-
vested and replaced 3 times weekly. Cell viability was measured using
AlamarBlue at day 27. Biomarkers released to the supernatant were
measured using the following well-described ELISA; C2M and AGNx2
reﬂecting matrix metalloproteinase (MMP)-mediated degradation of
type II collagen and aggrecan, respectively, AGNx1 reﬂecting aggreca-
nase-mediated degradation of aggrecan, and C-Col10 reﬂecting chon-
drocyte hypertrophy. Mean values and standard error of the mean
(SEM) were compared using one-way ANOVA assuming normal dis-
tribution. Signiﬁcance levels are indicated by asterisks; *P < 0.05, **P <
0.01.
Results: To evaluate the changes in matrix degradation occurring in
the FDCex in response to direct stimulation with rhFGF18, three
different biomarkers of matrix degradation were quantiﬁed (ﬁgure
1). According to C2M, MMP-mediated type II collagen degradation is
signiﬁcantly decreased in response to  50 ng/mL rhFGF18 from day
11 onward (P < 0.05). Likewise, AGNx2 indicates a slight decrease
in MMP-mediated aggrecan degradation in response to  50 ng/mL
rhFGF18 from day 18 onward, although not signiﬁcant. On the
contrary, AGNx1 reveals increased aggrecanase-mediated aggrecan
degradation in response to  10 ng/mL rhFGF18 at day 25, although
only signiﬁcant for 50 ng/mL rhFGF18 (P < 0.05). Evaluation of the
chondrocytic changes occurring in response to rhFGF18, reveal a
dose-dependent increase in cell viability measured at day 27, and
no indication of hypertrophic cell differentiation, as assessed by C-
Col10.
Conclusions: The data presented here indicate that direct stim-
ulation of articular cartilage with rhFGF18 leads to decreased gen-
eration of MMP-mediated cleavage fragments of type II collagen and
aggrecan, but increased generation of the aggrecanase-mediated
cleavage fragment of aggrecan. Interestingly, AGNx2 is believed to be
a marker of cartilage degradation with impaired repair capacity,
whereas AGNx1 is considered a marker of reversible form cartilage
degradation. Accordingly, the increased AGNx1 could indicate the
matrix degradation needed for expansion of the lacunae, which
according to our hypothesis is needed to initiate the process of
cartilage formation. Clarifying the steps of this process is highly
important for the understanding of how a potential novel DMOAD is
affecting the tissue.121
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Purpose: The gold standard for assessing joint damage is still the plain
radiograph and this method only provides a historical view of the
skeletal damage that has already occurred. We cannot predict OA pro-
gression from the radiograph. In contrast, biomarkers are candidates to
predict an event that would occur in OA. One of the primary disease
processes of osteoarthritis is degradation of the type II collagen, which
is most abundant and highly speciﬁc for cartilage tissue. Crosslinked
telopeptide of type II collagen (CTX-II) was one of the speciﬁc marker of
type II collagen degradation in cartilage. Monitoring urine (u) CTX-II
was considered to be a potential biomarker in knee OA. It is reported
that uCTX-II was correlated with prevalence of radiographic OA and
higher uCTX-II had a increasing risk of having OA. However, there were
few reports about its role for prediction of OA progression. The purpose
of this study was to investigate whether uCTX-II could predict OA
progression.
Methods: This prospective cohort study protocol was approved by the
institutional review board of our university. One hundred and fourteen
painful medial knee OA patients were enrolled in this study. Some of the
patients were excluded due to data and follow up missing. Ninety one
patients (71.5y in average, men/female: 9/82) were analyzed. The basal
characteristics of the patients and a standing, extended antero-
